← All trials
NCT03372473
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2016
- Primary completion
- Feb 1, 2016
- Completion date
- Jun 30, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hospital General Dr. Manuel Gea GonzalezLead sponsor
- Government of MexicoCollaborator
- Hospital General Dr. Manuel Gea GonzalezOverall official - principal investigator
- Hospital General Dr. Manuel Gea GonzalezReponsible party - principal investigator
- Laboratorios Senosiain, S.A. de C.V.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.